MOKAN Wealth Management Inc. Buys New Stake in Johnson & Johnson (NYSE:JNJ)

MOKAN Wealth Management Inc. purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 12,026 shares of the company's stock, valued at approximately $1,739,000. Johnson & Johnson makes up about 1.1% of MOKAN Wealth Management Inc.'s portfolio, making the stock its 24th largest position.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. IFS Advisors LLC increased its holdings in Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after buying an additional 100 shares during the period. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $35,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $32,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after buying an additional 91 shares during the period. Institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock traded up $3.27 during mid-day trading on Friday, hitting $162.95. 6,695,360 shares of the stock were exchanged, compared to its average volume of 8,885,373. The firm has a fifty day moving average of $148.61 and a 200 day moving average of $155.89. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a market cap of $392.32 billion, a PE ratio of 24.49, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the company posted $2.29 EPS. The company's revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's payout ratio is currently 74.59%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on JNJ shares. Guggenheim lifted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a report on Monday, February 3rd. Leerink Partners cut their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 28th. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.